{"id":195242,"date":"2018-12-25T04:11:02","date_gmt":"2018-12-25T09:11:02","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=195242"},"modified":"2025-03-08T03:01:18","modified_gmt":"2025-03-08T08:01:18","slug":"cancer-killing-treatment-approved-in-australia","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2018\/12\/25\/cancer-killing-treatment-approved-in-australia\/","title":{"rendered":"Cancer-killing treatment approved in Australia"},"content":{"rendered":"
\n
\"\"<\/a>
Prior to the TGA approving the treatment, patients with aggressive blood cancers who had exhausted all other treatments had been traveling overseas to be treated. (Pixabay file photo)<\/figcaption><\/figure>\n<\/div>\n
<\/div>\n
CANBERRA\u00a0— A “revolutionary” cancer drug that supercharges immune cells to hunt and kill cancer cells has been approved for human use in Australia.<\/div>\n
<\/div>\n
The Therapeutic Goods Administration (TGA) on Wednesday announced that CAR-T therapy has been approved for use in pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia (ALL) and adults with diffuse large B cell lymphoma (DLBCL).<\/div>\n
<\/div>\n
CAR-T therapy trains immune cells to fight and kill cancer cells by first extracting them from a patient’s body to genetically re-engineer them before infusing them back into the body.<\/div>\n
<\/div>\n
Prior to the TGA approving the treatment, patients with aggressive blood cancers who had exhausted all other treatments had been traveling overseas to be treated.<\/div>\n
<\/div>\n
Daniel Clarke, 45, traveled with his family to the United States so he could receive CAR-T treatment for his DLBCL. Within one month, his cancer had vanished.<\/p>\n
buy oseltamivir online https:\/\/bereniceelectrolysis.com\/images\/ORIGINALS\/png\/oseltamivir.html<\/a> no prescription pharmacy <\/div>\n

<\/div>\n

<\/div>\n
“I felt like someone had just handed my life back to me,” he told Fairfax Media on Wednesday.<\/p>\n
buy methocarbamol online https:\/\/bereniceelectrolysis.com\/images\/ORIGINALS\/png\/methocarbamol.html<\/a> no prescription pharmacy <\/div>\n

<\/div>\n

<\/div>\n
“It has all happened so quickly. Late September, we (went to Boston) not knowing what to expect, hoping for the best, fearing the worst. Then, come November, I was in complete remission.”<\/div>\n
<\/div>\n
Global pharmaceutical giant Novartis owns the therapy and has already increased production to keep up with global demand.<\/div>\n
<\/div>\n
“We are focused on ramping up capacity at our US and Switzerland facilities and we recently announced a collaboration agreement for additional manufacturing capacity with Fraunhofer (Germany) and CellforCure (France),” spokesperson Lauren Carey said.<\/div>\n
<\/div>\n
“These additional manufacturing facilities are intended to support production on a global scale.”<\/div>\n
<\/div>\n
However, CAR-T therapy is not classified as a “drug” so it cannot be subsidized by the Pharmaceutical Benefits Scheme.<\/div>\n
<\/div>\n
Patients who undergo the treatment in Australia face an out-of-pocket cost of up to 598,000 Australian dollars.<\/p>\n
buy cleocin online https:\/\/bereniceelectrolysis.com\/images\/ORIGINALS\/png\/cleocin.html<\/a> no prescription pharmacy <\/div>\n

<\/div>\n

<\/div>\n
Greg Hunt, Australia’s Minister for Health, has flagged his intention to have the treatment subsidized as soon as possible.<\/div>\n","protected":false},"excerpt":{"rendered":"

CANBERRA\u00a0— A “revolutionary” cancer drug that supercharges immune cells to hunt and kill cancer cells has been approved for human …<\/p>\n","protected":false},"author":33,"featured_media":195243,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[],"class_list":["post-195242","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","mauthors-philippine-news-agency"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/195242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=195242"}],"version-history":[{"count":1,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/195242\/revisions"}],"predecessor-version":[{"id":287690,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/195242\/revisions\/287690"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/195243"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=195242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=195242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=195242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}